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introduction
This article summarizes the scientific concepts underlying 
pragmatic clinical trials as a research technique that is worthy 
of wider use in dermatology. 
Pragmatic trials
Pragmatic clinical trials seek to determine the effectiveness 
of an intervention in a real-world setting to inform clinical 
decision making (Roland and Torgerson, 1998). Researchers 
designing pragmatic trials take particular care to ensure that 
the study population is as similar as possible to the population 
on which the intervention is meant to be used (external valid-
ity), reflecting the normal range of diversity in disease severity, 
comorbidities, age, sex, and social and ethnic groups seen in 
everyday clinical practice. Pragmatic trials also ensure that the 
sorts of interventions tested can be plausibly rolled out in clini-
cal practice and that the outcomes used to assess effectiveness 
are valid and easily understood by a range of users, including 
clinicians, patients, policy makers, and health commissioners. 
Pragmatic clinical trial patients may also be used to test “strat-
egies” or treatment policies rather than one specific drug at a 
time. For example, the BLISTER (Bullous Pemphigoid Steroids 
and Tetracyclines Study) randomized controlled trial tests the 
policy of starting treatment for bullous pemphigoid patients 
with either doxycycline or prednisolone (Chalmers et al., 
2015). The policy evaluates the trade-off between the short-
term smaller benefit for blister control, as might be anticipated 
for doxycycline, and the long-term safety concerns that may 
disadvantage patients randomized to prednisolone. It does not 
matter whether the dose of prednisolone is altered during the 
study as would normally occur in clinical practice, nor does it 
matter if some of the patients initially randomized to the strat-
egy of starting with doxycycline are switched subsequently to 
prednisolone—what matters is a comparison of the two strat-
egies to which the participants were originally randomized. 
Cost-effectiveness analysis is usually a key component of prag-
matic trials to enable care providers to make informed deci-
sions on value for money (Thomas et al., 2006).
•	 Pragmatic	clinical	trials	seek	to	answer	important	
	 questions	that	are	applicable	to	everyday	clinical	
	 practice.
•	 The	design	of	pragmatic	trials	aims	to	test	an	
	 intervention	in	a	study	environment	that	is	closer	
	 to	real	life	in	terms	of	study	population,	
	 intervention,	comparator,	and	outcomes.
•	 Pragmatic	trials	must	still	adhere	to	the	stringent	
	 trial	methods	for	minimizing	selection,	
	 performance,	information,	attrition,	selective	
	 outcome	reporting,	and	publication	bias.
•	 Pragmatic	trials	must	be	prospectively	registered	
	 and	reported	fully	according	to	the	pragmatic	trials	
	 extension	of	the	CONSORT	statement.
•	 The	PRECIS	tool	is	one	method	for	assessing	
	 where	on	the	pragmatic–explanatory	continuum	
	 a	trial	resides	and	which	aspects	are	more	
	 pragmatic	or	explanatory.
•	 More	pragmatic	trials	should	be	considered	
	 in	dermatology	so	that	they	better	inform	
	 patient	care.
•	
•	
•	 Pragmatic	clinical	trials	can	cost	more	than	
	 explanatory	trials,	and	may	require	a	more	
	 complex	study	design.
•	 The	majority	of	clinical	trials	are	neither	entirely	
	 pragmatic	nor	entirely	explanatory—they	are	part	
	 of	a	continuum.
•	 Pragmatic	trials	are	not	suitable	for	early	trials	
	 that	seek	to	explore	whether	a	new	experimental	
	 intervention	shows	any	biological	effect.
What Pragmatic clinical trials do
limitations
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table 1.  Picot comparison—a comparison of pragmatic versus explana-
tory trials in dermatology in terms of their five main components: patients, 
intervention, comparison, outcome, and time of assessment
Pragmatic trial: tests effectiveness Explanatory trial: test’s efficacy
Real-life patients Homogeneous patients
Flexible intervention with changes Tightly defined intervention
Active comparator instead of 
placebo
Clearly defined control group, often 
placebo
Clinically important outcomes Objective/surrogate outcomes
Longer-term follow-up times 
(e.g., 6 months)
Short-term follow-up time 
(e.g., 6 weeks)
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matism for 10 features on the PRECIS tool (Bratton et al., 2012). 
For example, flexibility of the experimental intervention that 
permitted investigators to alter the dose of oral corticosteroids 
for bullous pemphigoid patients in a way that reflected normal 
clinical practice resulted in a mean score toward the outer prag-
matic boundary of the PRECIS wheel, whereas the domain of 
“eligibility criteria” scored somewhere between the pragmatic 
outer boundary and the explanatory center of the wheel—prob-
ably as a result of exclusion of patients with dementia. The 
resultant diagrams, which resemble spiderwebs, provide an 
immediate visual guide as to how pragmatic a study is overall 
and where the most pragmatic elements reside. Highly explana-
tory trials show a “web” that is closely tucked into the center, 
whereas pragmatic trials are dispersed toward the periphery. 
The PRECIS wheel can be used both at the design stage and 
when trying to assess the degree of pragmatism in an ongoing or 
published study (Bratton et al., 2012).
limitations of thE tEchniquE
There is a perception that pragmatic trials are equivalent to say-
ing that “anything goes.” Although this is true for some aspects, 
such as allowing flexible dosing for reasons of safety and to 
mimic how the intervention might be delivered in clinical 
practice, all critical aspects to reduce bias—e.g., randomiza-
tion, blinding, treating both groups equally, and analyzing all 
those originally randomized—must be adhered to (Williams 
and Gilchrest, 2015). Sometimes blinding of the intervention (as 
in surgical procedures) is simply not possible, yet it is almost 
always possible to ensure a blinded evaluation of outcome. 
Pragmatic clinical trials are usually more expensive to conduct 
than explanatory trials because they are typically larger in order 
to identify minimally clinically important differences in real-
life settings. They often require longer follow-up and additional 
cost-effectiveness analyses, which can add to study complexity 
and cost. Feasibility work or explanatory trials are often needed 
before embarking on such studies. Like all study designs, there 
are good and bad pragmatic studies, and like all clinical trials 
published in the JID and elsewhere, they must be fully registered 
and reported fully using the pragmatic-trials extension of the 
Consolidated Standards of Reporting Trials (CONSORT; http://
www.consort-statement.org/extensions?ContentWidgetId=556) 
so that the reader can judge study quality.
Which is bEst?
Despite the widespread publication and acceptance of prag-
matic clinical trials as the cornerstone of primary research for 
health technology assessment in the top general medical jour-
nals (Thomas et al., 2013), they are still not widely understood 
or conducted in dermatology, where explanatory trials still 
appear to be the norm (Williams and Dellavalle, 2012). For 
example, a PubMed search (11 February 2015) using the terms 
“dermatology AND randomized AND pragmatic” found only 
15 citations, of which only 5 were completed studies, compared 
with an estimated 5,000 randomized controlled clinical trials in 
dermatology as a whole. Perhaps the small yield of pragmatic 
studies in the above search is due to the fact that many such 
studies fail to mention the term “pragmatic” in the title or study 
text, a feature that can be righted easily by making the design 
ExPlanatory trials
Explanatory clinical trials, on the other hand, seek to deter-
mine the efficacy of an intervention under ideal conditions. 
Participants are often a highly selected and homogenous group 
exhibiting good compliance, and are usually recruited in sec-
ondary or tertiary care (Treweek and Zwarenstein, 2009). 
Participants are more likely to remain in the study, typically 
have only the target condition, and are subject to strict dosing 
schedules and monitoring. Explanatory trials are deliberately 
designed to give the maximum chance of showing an effect, 
if one is present. Outcomes may include cellular markers that 
explore disease mechanisms (Papp et al., 2012), as well as com-
posite clinical scales for assessing clinical efficacy. Per protocol 
analysis tends to be carried out and cost-effectiveness analyses 
are unusual. Explanatory trials thus typically answer the ques-
tion “can this treatment work under ideal conditions?” They usu-
ally precede pragmatic trials which then ask “we now know it 
can work, but how well does it work in real world clinical prac-
tice?”  Table 1 shows the contrasting features between a  typical 
pragmatic and explanatory trial in terms of patients, interven-
tion, comparison, outcome and time of assessment (PICOT 
framework).
thE Pragmatic/ExPlanatory continuum and thE 
PrEcis WhEEl
Having described the main differences between pragmatic 
and explanatory trials to aid understanding of their underlying 
concepts, it is important to recognize the limitations of such a 
dichotomous approach because most trials contain components 
of both approaches. This concept of a continuum has led to the 
development of a useful method to assess the degree of prag-
matism when designing a clinical trial, called the Pragmatic–
Explanatory Continuum Indicator Summary (PRECIS) tool 
(Thorpe et al., 2009). Figure 1 shows how investigators of the 
BLISTER trial (www.blistertrial.co.uk) rated the degree of prag-
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figure 1.  PrEcis wheel showing the mean of the scores given by blistEr 
trial management group members (solid line). Also presented are the most 
explanatory scores (inner line) and most pragmatic scores (outer line) given 
in each domain. Scores were plotted on the wheel using a simple picture-
editing program (Bratton et al., 2012).
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clear in the study title and description. The choice of an explan-
atory or pragmatic design clearly depends on the perspective 
of the question and where in the research cycle the technol-
ogy being tested is positioned. New drugs or devices typically 
require explanatory trials when testing whether the interven-
tion demonstrates clinical benefit against vehicle or placebo. 
Placebo-controlled explanatory trials rarely inform clinical 
practice because it is unusual to use placebos in clinical prac-
tice and because patients are not typically perfectly adherent to 
the prescribed treatment for various reasons. Those interventions 
that have shown efficacy against placebo should then be tested 
for effectiveness against active comparators using pragmatic 
designs. Pragmatic clinical trials are the cornerstone of the com-
parative effectiveness agenda (Agency for Healthcare Research 
and Quality), which has gained significant funds from the 2009 
US Government American Recovery and Reinvestment Act (Sox 
and Greenfield, 2009). Most of the definitive national clinical 
trials funded by the UK National Institute of Health Research 
Health Technology Assessment Board are also pragmatic in 
nature (http://www.nets.nihr.ac.uk/programmes/hta).
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1. What is not a typical component of a pragmatic 
 trial?
A. Designed to assess clinical effectiveness. 
B. Highly selected patients with no comorbidities.
C. Includes study population similar to real-life 
 population. 
D. Cost-effectiveness analysis. 
2. What is the main aim of an explanatory trial?
A. To compare strategies of treatment. 
B. To evaluate how the intervention will work in 
 everyday clinical practice. 
C. To determine efficacy.
D.  To assess rare adverse effects. 
3. most trials in clinical dermatology can be 
 considered
A. Pragmatic.
B. Explanatory.
C. Neither A nor B.
D. A continuum of A and B.
4. Which statement regarding the PrEcis tool is 
 correct?
A. The acronym stands for Pragmatic-Explanatory 
 Continuum Indicator Summary tool.
B. It provides a numerical rating of pragmatism.
C. It contains eight assessment features.
D. Explanatory trials show a “web” towards the 
 periphery.
5. Which statement is true regarding a pragmatic trial?
A. They are typically more costly due to trial size 
 and cost-effectiveness analysis.
B. They often require background feasibility or 
 explanatory work beforehand.
C. They are the cornerstone of the comparative 
 effectiveness agenda.
D. All of the above.
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